Clinical Trial Update: A Trial to Evaluate Safety and Efficacy of a Product Named VGN-R08b in Parkinson's Disease Patients With GBA1 Mutations [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 clinical trial evaluating the safety and efficacy of VGN-R08b in Parkinson's disease patients with GBA1 mutations; the study is not yet recruiting.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Parkinson Disease

Drugs mentioned

• VGN-R08b

Snippet

Sponsor: Shanghai Vitalgen BioPharma Co., Ltd. | Conditions: Parkinson Disease (PD) | Phase 1, Phase 2 | Status: NOT_YET_RECRUITING